Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
135.42
+0.46 (0.34%)
Dec 20, 2024, 4:00 PM EST - Market closed
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
The 21 analysts with 12-month price forecasts for NBIX stock have an average target of 166, with a low estimate of 114 and a high estimate of 219. The average target predicts an increase of 22.58% from the current stock price of 135.42.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NBIX stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 8 | 8 | 6 |
| Buy | 10 | 11 | 11 | 11 | 11 | 11 |
| Hold | 6 | 5 | 5 | 5 | 5 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 23 | 24 | 24 | 24 | 24 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Dec 20, 2024 |
| Wedbush | Wedbush | Buy Reiterates $148 | Buy | Reiterates | $148 | +9.29% | Dec 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $190 | Strong Buy | Reiterates | $190 | +40.30% | Dec 16, 2024 |
| Needham | Needham | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Nov 11, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $190 | Strong Buy | Reiterates | $190 | +40.30% | Nov 1, 2024 |
Financial Forecast
Revenue This Year
2.40B
from 1.89B
Increased by 27.07%
Revenue Next Year
2.80B
from 2.40B
Increased by 16.60%
EPS This Year
4.20
from 2.47
Increased by 69.97%
EPS Next Year
6.21
from 4.20
Increased by 47.97%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 2.5B | 3.1B | 3.7B | |||
| Avg | 2.4B | 2.8B | 3.3B | |||
| Low | 2.2B | 2.5B | 2.7B |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 33.5% | 29.8% | 32.9% | |||
| Avg | 27.1% | 16.6% | 16.8% | |||
| Low | 15.0% | 2.2% | -2.0% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 6.33 | 7.84 | 12.86 | |||
| Avg | 4.20 | 6.21 | 8.81 | |||
| Low | 3.55 | 3.58 | 5.33 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 156.3% | 86.8% | 107.1% | |||
| Avg | 70.0% | 48.0% | 41.8% | |||
| Low | 43.6% | -14.8% | -14.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.